Robert F. Cornell

6.2k total citations
80 papers, 1.3k citations indexed

About

Robert F. Cornell is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert F. Cornell has authored 80 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Hematology, 44 papers in Molecular Biology and 36 papers in Oncology. Recurrent topics in Robert F. Cornell's work include Multiple Myeloma Research and Treatments (55 papers), Protein Degradation and Inhibitors (26 papers) and Peptidase Inhibition and Analysis (16 papers). Robert F. Cornell is often cited by papers focused on Multiple Myeloma Research and Treatments (55 papers), Protein Degradation and Inhibitors (26 papers) and Peptidase Inhibition and Analysis (16 papers). Robert F. Cornell collaborates with scholars based in United States, Canada and Switzerland. Robert F. Cornell's co-authors include Parameswaran Hari, Daniel J. Lenihan, Adetola A. Kassim, Luciano J. Costa, William R. Drobyski, Saurabh Chhabra, Kelly Godby, Javid J. Moslehi, Bonnie Ky and Joseph R. Carver and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert F. Cornell

74 papers receiving 1.3k citations

Peers

Robert F. Cornell
Francesca Elice Italy
Brandi Reeves United States
Evangelos Eleutherakis‐Papaiakovou Greece
Brea Lipe United States
Seongseok Yun United States
Yvette C. Tanhehco United States
Nikolaos Kanellias Greece
Leonard T. Heffner United States
Apostolos Kontzias United States
Dimitrios Christoulas Greece
Francesca Elice Italy
Robert F. Cornell
Citations per year, relative to Robert F. Cornell Robert F. Cornell (= 1×) peers Francesca Elice

Countries citing papers authored by Robert F. Cornell

Since Specialization
Citations

This map shows the geographic impact of Robert F. Cornell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert F. Cornell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert F. Cornell more than expected).

Fields of papers citing papers by Robert F. Cornell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert F. Cornell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert F. Cornell. The network helps show where Robert F. Cornell may publish in the future.

Co-authorship network of co-authors of Robert F. Cornell

This figure shows the co-authorship network connecting the top 25 collaborators of Robert F. Cornell. A scholar is included among the top collaborators of Robert F. Cornell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert F. Cornell. Robert F. Cornell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Williams, Roy, Samuel M. Rubinstein, Timothy J. Garrett, et al.. (2024). Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma. Clinical and Translational Science. 17(5). e13828–e13828. 1 indexed citations
2.
3.
Mıkhael, Joseph, et al.. (2023). Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities. Clinical Lymphoma Myeloma & Leukemia. 24(2). e1–e12. 5 indexed citations
4.
Yang, Guang, Samuel M. Rubinstein, Robert F. Cornell, et al.. (2023). Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Frontiers in Cardiovascular Medicine. 10. 1181806–1181806. 4 indexed citations
5.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901. 71 indexed citations
6.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations
7.
Chen, Elaine C., Samuel M. Rubinstein, Cinque Soto, et al.. (2020). Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis. PLoS ONE. 15(7). e0235713–e0235713. 1 indexed citations
8.
Rubinstein, Samuel M., et al.. (2020). Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Frontiers in Oncology. 10. 815–815. 21 indexed citations
9.
Garrett, Timothy J., Sonal Singh, Chintan Shah, et al.. (2020). Abstract 15012: Lactate Dehydrogenase B and Pyruvate Oxidation Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: A Multi-omics Study. Circulation. 142(Suppl_3). 1 indexed citations
10.
Cornell, Robert F., et al.. (2018). Advances in Treatment of Cardiac Amyloid. Current Treatment Options in Cardiovascular Medicine. 20(5). 37–37. 8 indexed citations
11.
Phillips, Sharon, Michael Byrne, Wichai Chinratanalab, et al.. (2018). Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation. 53(6). 701–707. 13 indexed citations
12.
Chari, Ajai, Saulius Girnius, Saurabh Chhabra, et al.. (2017). Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 130. 3111–3111. 2 indexed citations
13.
Cornell, Robert F., et al.. (2017). Current Concepts of Cardiac Amyloidosis. Heart Failure Clinics. 13(2). 409–416. 27 indexed citations
14.
Lenihan, Daniel J., et al.. (2017). Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. Cardio-Oncology. 3(1). 4–4. 22 indexed citations
15.
Oke, Oluchi, Tarsheen Sethi, Stacey Goodman, et al.. (2017). Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 23(9). 1473–1477. 6 indexed citations
16.
Cornell, Robert F., et al.. (2016). Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision‐making. American Journal of Hematology. 91(10). 1044–1051. 8 indexed citations
17.
Cornell, Robert F. & Adetola A. Kassim. (2016). Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation. 51(4). 479–491. 73 indexed citations
18.
Johnpulle, Romany, Sophie Paczesny, Dae Kwang Jung, et al.. (2016). Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. Biology of Blood and Marrow Transplantation. 23(3). 529–532. 13 indexed citations
19.
Cornell, Robert F., Xiaobo Zhong, Carlos Arce‐Lara, et al.. (2015). Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplantation. 50(7). 914–917. 21 indexed citations
20.
Cornell, Robert F. & Jeanne Palmer. (2012). Adult Acute Leukemia. Disease-a-Month. 58(4). 219–238. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Elice Breakdown of academic impact, for papers by Brandi Reeves Breakdown of academic impact, for papers by Evangelos Eleutherakis‐Papaiakovou Breakdown of academic impact, for papers by Brea Lipe Breakdown of academic impact, for papers by Seongseok Yun Breakdown of academic impact, for papers by Yvette C. Tanhehco Breakdown of academic impact, for papers by Nikolaos Kanellias Breakdown of academic impact, for papers by Leonard T. Heffner Breakdown of academic impact, for papers by Apostolos Kontzias Breakdown of academic impact, for papers by Dimitrios Christoulas
Rankless by CCL
2026